TY - JOUR
T1 - Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials
AU - Decary, Simon
AU - Maarten de Wit
AU - Evans, Victoria
AU - Tugwell, Peter
AU - Toupin-April, Karine
N1 - Funding Information:
The authors would like to thank Shawna Grosskleg, Laurie Proulx, Ayano Kelly, Lauren K. King, Jennifer Petkovic, Jessica Kaufman, Ian M. Disend and Andrea Boyd. We would like to thank the Canadian Arthritis Patient Alliance (CAPA), the EULAR PARE (People with Arthritis and Rheumatism) network and EULAR PRPs, GRAPPA (Group for Research of Psoriasis and Psoriatic Arthritis) PRPs, the International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis), Creaky Joints, Joint Health, SAVVY Coop, S.T.A.R Initiative, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Cochrane Musculoskeletal consumer group, Versus Arthritis UK, Arthritis Care Netherlands, Vasculitis UK, Osteoarthritis Research Society International (OARSI), Dragon Claw and the Canadian Rheumatology Association.
Funding Information:
Funding for travel awards to the OMERACT conference were provided by OMERACT. K. Toupin-April is funded by The Arthritis Society, the Chronic Pain Network (a Network funded by the Canadian Institutes of Health Research (CIHR) Strategy for Patient Oriented Research (SPOR), the Ontario Ministry of Economic Development, Job Creation and Trade and the Children's Hospital of Eastern Ontario Research Institute. S. Décary received a Banting postdoctoral salary award from Canadian Institutes of Health Research. J. L. Barton's research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under Award Number K23AR-064372. L. Fraenkel's research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under Award Number AR060231– 01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. L. C. Li holds the Harold Robinson/Arthritis Society Chair in Arthritic Diseases, and is supported by the Canada Research Chair Program. D. Stacey holds a University of Ottawa Research Chair in Knowledge Translation to Patients. R. Christensen's research at the Parker Institute is supported by grants from The Oak Foundation (OCAY-13–309). L. March's research is supported by the Northern Sydney Local Health District. S. Sharma is supported by the International Association for the Study of Pain John J. Bonica Postdoctoral Fellowship.
Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/1/15
Y1 - 2024/1/15
N2 - Objective: To gain consensus on the definitions and descriptions of the domains of the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials evaluating shared decision making (SDM) interventions. Methods: Following the OMERACT Handbook methods, our Working Group (WG), comprised of 90 members, including 17 patient research partners (PRPs) and 73 clinicians and researchers, had six virtual meetings in addition to email exchanges to develop draft definitions and descriptions. The WG then conducted an international survey of its members to gain consensus on the definitions and descriptions. Finally, the WG members had virtual meetings and e-mail exchanges to review survey results and finalize names, definitions and descriptions of the domains. Results: WG members contributed to developing the definitions. Fifty-two members representing four continents and 13 countries completed the survey, including 15 PRPs, 33 clinicians and 37 researchers. PRPs and clinicians/researchers agreed with all definitions and descriptions with agreements ranging from 87% to 100%. Respondents suggested wording changes to the names, definitions and descriptions to better reflect the domains. Discussions led to further simplification and clarification to address common questions/concerns about the domains. Conclusion: Our WG reached consensus on the definitions and descriptions of the domains of the core domain set for rheumatology trials of SDM interventions. This step is crucial to understand each domain and provides the foundation to identify instruments to measure each domain for inclusion in the Core Outcome Measurement Set. Clinical significance: The current study provides consensus-based definitions and descriptions for the domains of the OMERACT core domain set for shared decision making interventions from patients/caregivers, clinicians and researchers. This is a crucial step to understand each domain and provides the foundation to identify instruments to measure each domain for inclusion in the Core Outcome Measurement Set for trials of SDM interventions.
AB - Objective: To gain consensus on the definitions and descriptions of the domains of the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials evaluating shared decision making (SDM) interventions. Methods: Following the OMERACT Handbook methods, our Working Group (WG), comprised of 90 members, including 17 patient research partners (PRPs) and 73 clinicians and researchers, had six virtual meetings in addition to email exchanges to develop draft definitions and descriptions. The WG then conducted an international survey of its members to gain consensus on the definitions and descriptions. Finally, the WG members had virtual meetings and e-mail exchanges to review survey results and finalize names, definitions and descriptions of the domains. Results: WG members contributed to developing the definitions. Fifty-two members representing four continents and 13 countries completed the survey, including 15 PRPs, 33 clinicians and 37 researchers. PRPs and clinicians/researchers agreed with all definitions and descriptions with agreements ranging from 87% to 100%. Respondents suggested wording changes to the names, definitions and descriptions to better reflect the domains. Discussions led to further simplification and clarification to address common questions/concerns about the domains. Conclusion: Our WG reached consensus on the definitions and descriptions of the domains of the core domain set for rheumatology trials of SDM interventions. This step is crucial to understand each domain and provides the foundation to identify instruments to measure each domain for inclusion in the Core Outcome Measurement Set. Clinical significance: The current study provides consensus-based definitions and descriptions for the domains of the OMERACT core domain set for shared decision making interventions from patients/caregivers, clinicians and researchers. This is a crucial step to understand each domain and provides the foundation to identify instruments to measure each domain for inclusion in the Core Outcome Measurement Set for trials of SDM interventions.
KW - Consensus-building
KW - Core domain set
KW - OMERACT
KW - Rheumatology
KW - Shared decision making
KW - Survey
UR - http://www.scopus.com/inward/record.url?scp=85184058113&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2024.152381
DO - 10.1016/j.semarthrit.2024.152381
M3 - Article
SN - 0049-0172
VL - 65
SP - 1
EP - 9
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
M1 - 152381
ER -